Advertisement
Advertisement
U.S. markets close in 2 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NightHawk Biosciences, Inc. (NHWK)

NYSE American - Nasdaq Real Time Price. Currency in USD
1.16000.0000 (0.00%)
As of 01:20PM EST. Market open.
Advertisement

NightHawk Biosciences, Inc.

627 Davis Drive
Suite 400
Morrisville, NC 27560
United States
919 240 7133
https://www.nighthawkbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey Alan Wolf J.D.Founder, Chairman, CEO & Pres1.31MN/A1963
Mr. William L. OstranderCFO & Sec.371.07kN/A1968
Dr. Justin Stebbing FRCP, FRCPath, M.A., M.D., Ph.D.Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardN/AN/AN/A
Colonel George E. Peoples Jr., F.A.C.S., FACS, M.D.Chief Medical AdvisorN/AN/AN/A
Dr. Anthony M. Manning Ph.D.Chief Scientific AdvisorN/AN/A1962
Dr. Paul W. Tebbey M.B.A., Ph.D.Sr. VP of Product Devel. & Portfolio StrategyN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Corporate Governance

NightHawk Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement